Let’s talk about what happens when science stops chasing youth and starts quantifying it. Generation Lab just raised $11M in seed funding, led by Accel, marking Accel’s 1st-ever longevity bet. Not a small move. Accel doesn’t throw darts at startup boards. They play chess, and they just made a bold opening move into the biotech future of staying younger, longer.
Founded by Alina Rui Su, Dr. Irina Conboy, and Michael Suswal, Generation Lab isn’t just talking about aging; they’re measuring it at the molecular level. Alina Rui Su, Harvard Med PhD, UC Berkeley bioengineering alum, Forbes 30 Under 30, and someone who filed her 1st medical patent at 15, teamed up with Dr. Irina Conboy, the UC Berkeley professor whose research on plasma dilution flipped aging biology on its head. Add Michael Suswal, co-founder of Standard AI and a man who knows how to scale systems from lab bench to market trench, and you’ve got a team built for impact.
Their platform, SystemAge™, doesn’t guess your biological age, it measures it. With over 460 epigenetic markers across 19 organ systems, Generation Lab can tell you how old your brain, heart, liver, or immune system really is. They call it “measuring biological noise.” Translation: the closer your body is to static, the younger you are. Clinical validation already shows results like a 13.6-year brain age reversal using MUSE Stemcell treatments. That’s not sci-fi. That’s data.
This seed round, featuring Samsung Next, Zone2, Steve Aoki’s Aoki Labs, Giannis Antetokounmpo’s BYL Ventures, and Simu Liu’s Markham Valley Ventures, pushes total funding to $15M. Big names, sure, but more importantly, diverse minds from entertainment, sports, and tech betting on longevity as the next frontier. When George Church, Aubrey de Grey, and Dr. Adeel Khan are on your scientific advisory board, you’re not following the trend; you’re building the timeline.
In under 10 months, Generation Lab has expanded to 275+ clinics across 18 countries, aggregating 300M+ data points. Their tech isn’t a supplement or a wellness app, it’s clinical-grade diagnostics built to turn healthspan into a measurable metric. The company’s HQ in SF might be small, but the ambition isn’t.
The play here isn’t immortality, it’s accountability. Knowing how your organs are aging before symptoms show up changes the entire conversation around healthcare. Generation Lab isn’t selling forever; they’re selling control. That’s the kind of disruption Accel just paid attention to.
